130 days ago • Posted by William Ramstein

Could Gilead see further growth from Veklury segment ?

Shares of Gilead Sciences added 2.5% premarket after the drug maker said demand for Veklury, its treatment for some Covid-19 patients, helped to drive fourth-quarter sales higher. - WSJ

#Stocks
bg_nwsletter